All In Biotech

Drug Trial Radar · NCT06106672

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-106 in Subjects Ages 18-75 With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

May 30, 2024

Primary completion

Jun 2026

Study completion Aug 2026

Sponsor

Sponsor type
Industry
First posted
Oct 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.

Conditions

  • Myasthenia Gravis
  • Generalized Myasthenia
  • AChR Myasthenia Gravis
  • MuSK MG

Interventions

  • CNP-106Drug

    CNP-106 is comprised of an antigenic AChR Peptide Pool (\~1 μg of each AChRα and AChRε peptide comprising AChR Peptide Pool Drug Substance per mg particles) dispersed within a negatively charged (-30 to -60 mV) polymer matrix of PLGA (Poly (DL-lactide-co-glycolide, 50:50 acid-end group)) particles (400-800 nm in size).

  • PlaceboOther

    CNP-106 Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs),Time frame: Through study day 180

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Infusion for Health

    Brea, California

  • University of California, Irvine

    Orange, California

  • University of California, Davis

    Sacramento, California

  • Yale University

    New Haven, Connecticut

  • Atlantis Research

    Miami, Florida

  • Quantix Research, LLC

    Miami, Florida

  • University of South Florida

    Tampa, Florida

  • Insight Hospital and Medical Center

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Insight Research Institute, Dearborn

    Dearborn, Michigan

  • University of Missouri, NextGen Precision Health

    Columbia, Missouri

  • Ohio State University Wexner Medical Center

    Colombus, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

  • Nerve and Muscle Center of Texas

    Houston, Texas

  • Prolato Clinical Research Center

    Houston, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.